New stock news | It is reported that Wentai Medicine plans to list in Hong Kong, with a fundraising scale of approximately 100 to 200 million US dollars.

According to media reports, Chengdu Wentai Pharmaceutical Technology Co., Ltd. (referred to as Wentai Medicine) is considering listing in Hong Kong, with a planned fundraising scale of approximately 100 to 200 million US dollars. Public information shows that Wentai Medicine was established in April 2021 by several Ph.D.s from the Chinese Academy of Sciences. The company has been focusing on the research and development of small molecule drugs and biopharmaceuticals, focusing on the development of glucagon-like peptide-1 receptor agonists, mainly focusing on the fields of obesity and overweight. They are also expanding into typical metabolic diseases such as hypertension, diabetes, as well as obstructive sleep apnea syndrome, metabolic dysfunction-related nonalcoholic fatty liver disease, and Alzheimer's disease. The most anticipated pipeline of the company is the oral small molecule GLP-1 receptor agonist VCT220, also known as CX11. Public information shows that CX11 has undergone phase II clinical trials in China and has shown "competitive weight loss effects," with phase III clinical trials set to start at the end of 2024.